JB Pharma reported a 16% YoY increase in Q2FY25 net profit to Rs 175 crore, driven by 22% growth in domestic business.

Alembic Pharma reported a 12% YoY rise in Q2FY25 net profit to Rs 153 crore, driven by strong domestic and US market sales. Revenues grew 3% to Rs 1648 crore, while EBITDA declined 6%, with margins at ...

Indian stock markets bearish after Trump's victory, Sensex and Nifty drop over 1%, led by tech, auto, pharma, and banking stocks.

Benchmark Nifty 50 index crossed 10 days EMA for the first time since the start of this downtrend, which is a sign of bullish trend reversal. Next resistance for the Nifty is seen in the band of ...

Zealand Pharma A/S (ZLDPF) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to earnings of $0.18 per share a year ago. These ...

State Bank of India and TCS were among the top losers on the BSE Sensex, while gainers were Tata Motors, Tech M, JSW Steel, Sun Pharma and Asian Paints ...

Healthcare stocks performed well during Trump's first term, despite increased uninsured rates and reduced regulation. Click ...

With Donald Trump winning the U.S. presidential election, there's growing interest in how IT and Pharma stocks will perform in the coming months. Avinash Gorakshakar, Head of Research at Profitmart ...

Sensex was trading 848.48 points, or 1.06 per cent, lower at 79,529.65, with selling in private lenders such as ICICI Bank, HDFC Bank, oil-to-telecom major Reliance Industries Ltd and IT major Infosys ...

The victory of Donald Trump in the US presidential elections is set to boost the stock market, highlighted a report by Angle One Wealth. The report highlighted that Trump is seen as a pro-market ...

As Australian stocks struggle to keep up with a booming US market after the presidential election, investors are focusing on potential ASX winners and losers from Donald Trump’s policies.

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...